United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

vifor pharma uk ltd - ferric carboxymaltose - solution for injection - 50mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

vifor pharma uk ltd - ferric carboxymaltose - solution for injection - 50mg/1ml

Ireland - English - HPRA (Health Products Regulatory Authority)

vifor france - iron carboxymaltose - dispersion for injection/infusion - 50 iron milligram(s)/millilitre - iron, parenteral preparations

Malta - English - Medicines Authority

vifor france sa 100-101 terrasse boieldieu tour franklin la défense 8 92042 paris la défense cedex, france - iron - solution for infusion or injection - iron 50 mg/ml - antianemic preparations

Malta - English - Medicines Authority

vifor france sa 100-101 terrasse boieldieu tour franklin la défense 8 92042 paris la défense cedex, france - iron - solution for injection/infusion - iron 50 mg - antianemic preparations

Malta - English - Medicines Authority

vifor france sa 100-101 terrasse boieldieu tour franklin la défense 8 92042 paris la défense cedex, france - iron - solution for injection/infusion - iron 50 mg - antianemic preparations

United States - English - NLM (National Library of Medicine)

vifor (international) inc. - methoxy polyethylene glycol-epoetin beta (unii: lr3uxn0193) (methoxy polyethylene glycol-epoetin beta - unii:lr3uxn0193) - methoxy polyethylene glycol-epoetin beta 30 ug in 0.3 ml - mircera is indicated for the treatment of anemia associated with chronic kidney disease (ckd) in: limitations of use mircera is not indicated and is not recommended: mircera has not been shown to improve symptoms, physical functioning, or health-related quality of life. mircera is contraindicated in patients with: risk summary available data from a small number of published case reports and postmarketing experience with mircera use in pregnancy are insufficient to identify a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. chronic kidney disease is associated with maternal and embryo-fetal risks (see clinical considerations) . in animal reproduction studies, administration of methoxy polyethylene glycol-epoetin beta to rats and rabbits during pregnancy and lactation adversely affected offspring at doses 17-fold and greater than the recommended human dose (see data) . the estimated background risk of major birth defects and miscarriage for the indicated populatio

Canada - English - Health Canada

fresenius kabi canada ltd - ertapenem (ertapenem sodium) - powder for solution - 1g - ertapenem (ertapenem sodium) 1g - carbapenems

Ireland - English - HPRA (Health Products Regulatory Authority)

vifor france - iron polymaltose, folic acid - tablets chewable - 100 milligram - iron bivalent, oral preparations

Ireland - English - HPRA (Health Products Regulatory Authority)

vifor france - iron (iii) - hydroxide sucrose complex - solution for injection/infusion - 20  milligram(s)/millilitre - iron trivalent, oral preparations; saccharated iron oxide